MPMI, also known as 3-(N-methylpyrrolidin-3-ylmethyl)indole or as N-methyl-ñ,N-trimethylenetryptamine, is a pyrrolidinylmethylindole and cyclized tryptamine which acts as a serotonin receptor agonist. It has been studied as an analogue and trace impurity of the antimigraine drug eletriptan but is otherwise little known.
Analogues of MPMI include 4-HO-MPMI, 5-MeO-MPMI, 5F-MPMI, eletriptan, CP-122288, CP-135807, 10,11-secoergoline (ñ,N-Pip-T), pyr-T, SN-22, and ñ,N,N-trimethyltryptamine, among others.
MPMI is not a controlled substance in Canada as of 2025.
MPMI is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.